Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics' Q2 Revenues More Than Double

NEW YORK (GenomeWeb News) – Cellular Dynamics International today reported that its second quarter revenues increased 123 percent year over year, driven by sales of its iCell products.

The Madison, Wis.-based firm brought in total revenues of $2.8 million for the three months ended June 30, compared to $1.3 million for the second quarter of 2012. It said that the revenue growth was primarily attributable to growth in unit sales of its iCell human induced pluripotent stem cell-derived products.

It also noted that it reported the first product revenues of $170,000 from its MyCell products line. Those products are used for iPS cell reprogramming, genetic engineering, and cell differentiation.

CDI reported a net loss of $5.1 million, or $2.92 per share, for the quarter, compared to a net loss of $6.2 million, or $3.58 per share, for the second quarter of 2012.

The firm's R&D spending climbed 3 percent to $3.9 million from $3.8 million, and its SG&A expenses also rose 3 percent to $3.3 million from $3.2 million.

It finished the quarter with $33.5 million in cash and cash equivalents. But, subsequent to the end of the quarter, CDI completed an initial public offering that brought in net proceeds of around $43 million.

In Thursday morning trade on the Nasdaq, shares of CDI were up a fraction of 1 percent at $12.75.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.